SGLT2 inhibitors and GLP-1 receptor agonists lower cardiovascular risk in type 2 diabetes, but a recent review suggests that age modifies their benefit.
The post SGLT2 Inhibitors More Cardioprotective in Older Patients With Type 2 Diabetes first appeared on Physician’s Weekly.
